rs1046089 — PRRC2A Arg1740His

PRRC2A Arg1740His — The Immune-Linked Variant and Your Reproductive Clock

Buried deep in chromosome 6's major histocompatibility complex (MHC) class III region sits a gene called PRRC2A — also known as BAT2, or HLA-B Associated Transcript 2. At first glance, this immune-associated region seems an unlikely place to look for clues about reproductive lifespan. Yet a missense variant in PRRC2A, rs1046089 (Arg1740His), was identified in a landmark 2012 meta-analysis of 22 genome-wide association studies¹¹ meta-analysis of 22 genome-wide association studies
Stolk et al., Nature Genetics 2012, ReproGen consortium as one of 13 loci significantly associated with age at natural menopause — and it remains one of the few coding variants in the menopause GWAS landscape with a plausible immunological mechanism.

The Mechanism

PRRC2A is a large proline-rich protein located in the MHC class III region and functions at two distinct levels that may both matter for reproductive aging. First, as an m6A RNA reader²² m6A RNA reader
N6-methyladenosine (m6A) is the most abundant internal mRNA modification; reader proteins bind and interpret these marks to regulate transcript stability and translation, PRRC2A post-transcriptionally regulates target RNAs involved in cell division. Germ cell–specific knockout of Prrc2a in mice causes spermatocytes to arrest at metaphase I due to spindle disorganization and chromosome misalignment, establishing a direct role in meiotic fidelity.

Second, rs1046089 acts as a cis-expression quantitative trait locus (eQTL)³³ cis-expression quantitative trait locus (eQTL)
An eQTL is a genomic position where DNA variation correlates with changes in nearby gene expression levels in immune tissues: the A allele is associated with altered expression of HLA-DRB4 in monocytes and HLA-DQA1 in lymphoblastoid cell lines. These HLA class II molecules regulate antigen presentation and immune surveillance. The proposed model is that dysregulated HLA expression in immune cells leads to inappropriate immune activation within ovarian tissue, accelerating the inflammatory component of follicular atresia⁴⁴ follicular atresia
The natural process by which non-dominant follicles die; over a reproductive lifetime, 99.9% of the ~400,000 follicles a woman is born with are eliminated this way.

The Arg1740His substitution itself — a change from positively charged arginine to neutral histidine in exon 22 — is predicted to be damaging by SIFT analysis. Whether the missense change directly impairs PRRC2A function in ovarian cells, or whether it is primarily a marker for the eQTL effects on HLA expression, remains an active question.

The Evidence

The defining study is the ReproGen consortium meta-analysis of 22 GWAS studies⁵⁵ ReproGen consortium meta-analysis of 22 GWAS studies
Stolk et al. 2012, n=38,968 discovery + 14,435 replication, all European-ancestry women. rs1046089 reached genome-wide significance at P=1.63×10⁻¹⁶ with a beta of −0.213 years per A allele. This translates to approximately 11 weeks per allele, or about 22 weeks (~5 months) earlier menopause in AA homozygotes compared to GG individuals, on average.

A subsequent study using the same 17 confirmed variants⁶⁶ A subsequent study using the same 17 confirmed variants
Day et al. 2015 modeled the impact on early menopause risk and found rs1046089 contributes an odds ratio of approximately 1.16 (95% CI 1.11–1.22) for experiencing menopause before age 45. Women in the top quintile of a combined menopause-timing genetic risk score had a 2.47-fold higher odds of early menopause compared to those in the bottom quintile — a combined burden that the authors noted "was greater than the best-validated non-genetic risk factor, smoking."

Population-level replication has been mixed. The Mashhad cohort study in Iranian women found nominal associations between the A allele and primary ovarian insufficiency⁷⁷ primary ovarian insufficiency
POI is defined as loss of normal ovarian function before age 40; distinct from natural early menopause but sharing genetic architecture (OR 1.65, 95% CI 1.17–2.32, P=0.004 in the allelic model), though these did not survive Bonferroni correction. A Chinese replication cohort found borderline evidence, suggesting the effect may vary across ancestries. The African-ancestry frequency of the A allele (~50%) is notably higher than in Europeans (~35%), though ancestry-specific effect estimates are not yet established.

The rs1046089 A allele is also implicated in immune dysregulation beyond reproduction. Associations with type 1 diabetes and rheumatoid arthritis⁸⁸ type 1 diabetes and rheumatoid arthritis
HLA class III region variants often have pleiotropic immune effects; rs1046089 is part of a broader immune susceptibility locus have been reported in the MHC region, consistent with the PRRC2A eQTL mechanism affecting HLA expression.

Practical Implications

Because each A allele may shift menopause timing by roughly 2–3 months on average, this variant alone does not dramatically alter the reproductive lifespan for most carriers. However, rs1046089 sits within a broader polygenic architecture for menopause timing, and its combined effect with other menopause-timing variants — including MCM8 rs16991615 — can meaningfully concentrate risk. The primary value of knowing this result lies in motivating earlier baseline ovarian reserve assessment and fertility timeline planning rather than any specific treatment.

Anti-Müllerian hormone (AMH) is the most informative single biomarker for remaining ovarian reserve and is the appropriate test for women who want to contextualize this genetic result with their current biology. AMH trajectories, not single values, are most informative: a declining AMH trend in someone in their late 20s or early 30s warrants more urgent fertility counseling than a single borderline-low value at age 38.

For carriers planning pregnancies, the practical question is whether the genetic signal is sufficient to shift the timing of family planning decisions. For most AA homozygotes, the effect (~5 months earlier menopause on average) is modest in isolation. The variant becomes more actionable when combined with other menopause-timing risk variants or with clinical findings (declining AMH, elevated FSH, or a family history of early menopause).

Interactions

MCM8 rs16991615 (E341K): The most important interaction candidate in this category. MCM8 rs16991615 is a DNA repair variant with a larger individual effect on menopause timing (~1 year per allele) and a well-established association with AMH levels. Both rs16991615 and rs1046089 were identified in the same 2012 ReproGen meta-analysis. Carriers of the common GG genotype at MCM8 (associated with earlier/lower-AMH phenotype) who also carry the A allele at rs1046089 represent an additive-risk profile for earlier reproductive aging.

A proposed compound action: Women who carry GG at rs16991615 (MCM8) and one or more A alleles at rs1046089 (PRRC2A) have multiple independent menopause-timing hits converging on earlier ovarian aging. The combined recommendation would be to obtain a baseline AMH panel before age 30, establish a personal AMH trajectory with repeat testing at 2-year intervals through the early 30s, and discuss fertility timeline planning with a reproductive endocrinologist if AMH is declining or already below age-expected norms.